\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

obligations may continue. See Instruction 1(b).		
--	--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1	Address of Reporting Person [*] ON JAMES ANTHONY (First) (Middle) ENUE OF THE AMERICAS		2. Issuer Name and Ticker or Trading Symbol <u>ZIOPHARM ONCOLOGY INC</u> [ZIOP]		tionship of Reporting P all applicable) Director	erson(s) to Issuer 10% Owner		
(Last) BBDO	~ /		3. Date of Earliest Transaction (Month/Day/Year) 09/23/2009		Officer (give title below)	Other (specify below)		
1285 AVENUE OF THE AMERICAS			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	vidual or Joint/Group Filing (Check Applicable			
(Street) NEW YORK	NY	10019		X	Form filed by One Re Form filed by More th Person			
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities A Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)	
Common Stock, \$.001 par value	09/23/2009		A ⁽⁶⁾		30,000	Α	\$ <mark>0</mark>	45,000	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Director Stock Option (right to buy)	\$4.31							(1)	12/22/2014	Common Stock, \$.001 par value	15,029		15,029	D	
Director Stock Option (right to buy)	\$5.01							04/26/2006	04/26/2016	Common Stock	15,000		15,000	D	
Director Stock Option (right to buy)	\$6.49							(2)	12/13/2016	Common Stock	15,000		15,000	D	
Director Stock Option (right to buy)	\$4.85							(3)	06/18/2017	Common Stock	15,000		15,000	D	
Stock Option (right to buy)	\$2.73							(4)	12/12/2017	Common Stock	20,000		20,000	D	
Stock Option (right to buy)	\$0.7							(5)	05/13/2019	Common Stock	15,000		15,000	D	

Explanation of Responses:

1. 7,515 shares vest on 12/22/05 and 7,514 shares vest on 12/22/06.

2. 5,000 shares vest on each of 12/13/07, 12/13/08 and 12/13/09.

3. 5,000 shares vest on each of 6/18/08, 6/18/09 and 6/18/10.

4. 6,667 shares vest on each of 12/12/08 and 12/12/09; 6,666 shares vest on 12/12/10.

5. 5,000 shares vest on each of 12/31/09, 6/30/2010 and 12/31/2010.

6. Grant of restricted stock; restrictions lapse on 9/23/2010.

<u>/s/ James A. Cannon</u>

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.